Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You would think Collier would start buying shares himself to not let Mann pass him up on ownership % <grin>
I predict tomorrow we get a Tweet about Ischemic Stroke.
Mann wants his cheapies!
I actually can understand the need for the current dilution. They are setting up for the Theracap concussion clinical.
They might even be gearing up for ischemic study.
Hopefully they are also setting up for the heart clinical (that would be bigger news).
I just don't know if they are wanting to present and share that data prior to commencing actual clinical study.
I am hoping the heart news/data will be the catalyst for better financing.
As Biotech said, better financing can be a big catalyst to propel us upwards.
In the next official PR, ENDV should tell people to follow their Twitter for more frequent updates and news bits.
The concussion Tweet is general info. of their plans. I believe ENDV will release official PR once the clinical trial is officially setup/started.
No, found it on the clinicaltrials.gov site.
Sofpulse is FDA approved and being sold now. The clinical trial I referenced will help give additional scientific evidence to support the claims of what it can do.
News (small)!!!
New clinical study using Sofpulse is in recruiting patient status now.
Endonovo is not coordinating but at least our product us being used and tested.
This is a prospective randomized controlled double-blind interventional study comparing the effect of pulsed-electromagnetic field device (PEMF), pectoral interfascial block (PIB), and placebo on postoperative pain control. This study has the interdisciplinary cooperation of the regional anesthesia group, and the breast and plastic surgery divisions. All female patients with breast cancer evaluated at Columbia University Medical Center (CUMC) who are undergoing unilateral or bilateral mastectomy with tissue expander reconstruction will be offered enrollment in this prospective study.
This study may take 2 years to completion.
BMIC moved out of the way. Glad it was not an all day event.
I'll assume today's "withdrawal" is to gear up for the clinical trials.
We need private investor, conventional loan, or sales to bring in revenue to avoid this. Hopefully Sofpulse sales will assist soon enough.
We need some ground breaking news from Immunotronics to give us a nice SP boost.
I was leaning more towards Rio Grande Neuroscience with the Sofpulse device.
It seems they were on the downtrend of operations and sold off their PEMF assets to Endonovo. ADM manufacturers the Sofpulse.
Endonovo sent out a Tweet yesterday about Sofpulse. Their recent acquisition and marketing could spark increased orders.
Challenges of Sofpulse.
We have seen read some of the benefits of Sofpulse. Let's talk about the challenges.
Insurance companies will not cover the cost of the device. They don't view it as a device for wound healing. They look at it as a device for therapeutic deep heat (it provides heat inside the body to the targeted tissue, not directly to the outside of body).
There is nothing wrong with this. It still reduces inflammation, increases blood flow, makes connective tissue more flexible. But it seems drugs have the upper hand in the marketing.
Endonovo can make ground breaking news if they can market a device for chronic wound healing. I don't think there is any PEMF device that has FDA approval to be marketed for "wound healing". That could be the golden ticket for being covered under insurance.
Uh oh. Why is ICLD selling A/R to their own board members?
Is ICLD that short of cash to pay the bills?
Aaron....your inside input?
Was taking a look at the latest financials.
'The decrease in the engineering division is primarily the result of decreased sales volume from one customer. "
Does anyone here know who that customer is that they refer to?
Here is more detail of the study of the Sofpulse tweet today.
http://www.academia.edu/7784590/Effects_of_Pulsed_Electromagnetic_Fields_on_IL-1ß_and_Post_Operative_Pain_A_Double-Blind_Placebo-Controlled_Pilot_Study_in_Breast_Reduction_Patients
ENDV definitely knew the acquisition was in process. I had previously posted a Rio Grande PR that stated ENDV was going to purchase the PEMF assets (though the PR did not specifically mention ENDV it did hint at it due to the mention of the previous failed acquisition).
We can only hope ENDV can multitask with the their Immunotronics and the new technology.
While the heart result finalization is pending, ENDV management can be actively working to get the people clinical trial started with Theracap. This is one of the low hanging fruit from RGN. RGN had it all set up but never got it going for whatever reason (probably monetary).
I bet one of those 2 items will be the next PR, unless they unveil a new marketing strategy for Sofpulse. It's on the market now, but could use marketing assistance (not only a Tweet....hehe).
Endonovo still has time to register for the BIO CEO & Investor conference in N.Y. in Feb.
This would be a short trip for Mann and his IR guys in Pittsburgh to go to.
But they are probably too busy getting their ducks in a row from the acquisition to better market themselves. These conferences are probably scheduled too soon to be fully prepared to market themselves with the newly acquired technology.
I do not see any evidence of them attending as a presenter. Too bad. Lots of investors go to the Biotech Showcase.
Have we had the $8.00 MMs for a while or are they new since the acquisition? I never paid attention to the higher level MMs before.
In May when we get our 1st Quarter Earnings Report we should see the beginnings of actual recorded revenue from sales of Sofpulse.
Correct but the volume of purchases was a lot less. Only 3k shares on 1/3 and 1/4.
At least no days were skipped.
It definitely did not seem to be marketed by Rio Grande at all.
This should be immediate revenue opportunity for ENDV.
There is a FB page for it. I see a conference photo of it on display. Not sure from what year.
Here is a page of it being configured for pets.
www.veterinarypracticenews.com/assisi-relaunches-electromagnetic-healing-device/
Below is an exerpt from the actual clinical study of the device they reference in the Tweet.
Reduced pain. Faster healing.
What's not to like about it?
Results: Pulsed electromagnetic fields produced a 57 percent decrease in mean pain scores at 1 hour (p < 0.01) and a 300 percent decrease at 5 hours (p < 0.001), persisting to 48 hours postoperatively in the active versus the control group, along with a concomitant 2.2-fold reduction in narcotic use in active patients (p = 0.002). Mean IL-1ß concentration in the wound exudates of treated patients was 275 percent lower (p < 0.001). There were no significant differences found for tumor necrosis factor-a, vascular endothelial growth factor, or fibroblast growth factor-2 concentrations.
Conclusions: Pulsed electromagnetic field therapy significantly reduced postoperative pain and narcotic use in the immediate postoperative period. The reduction of IL-1ß in the wound exudate supports a mechanism that may involve manipulation of the dynamics of endogenous IL-1ß in the wound bed by means of a pulsed electromagnetic field effect on nitric oxide signaling, which could impact the speed and quality of wound repair.
Looks like they are starting to market the Sofpulse (Twitter update).
The next PR "update" will hopefully be heart news.
Then after that will be FDA registration completion to start clinical trials of Theracap.
Around the same time of this should be clinical trial of tPEMF to treat ischemic stroke.
Then we should be be due for some pre-clinical results of the other organs and conditions being treated with Immunotronics.
I wonder if they are gearing up for a new trial with an updated device? Or are they just advertising what they have and what it has been used for already.
Here is a link to the clinical trial.
https://clinicaltrials.gov/ct2/show/results/NCT01262599?term=PEMF&cond=Breast&rank=1
Good to see they are at least using Twitter to market themselves.
I don't understand how they can sit on that patent. Find a partner to assist with the research and marketability of the technology!!
Endonovo has also talked about MS research using Rio Grande's technology.
Here is the link for the patent filed by RGN:
https://www.google.com/patents/WO2016134367A1?cl=en
Although various PEMF studies in MS demonstrate positive outcomes overall, they have somewhat varied outcomes individually, which could be due to the specific device, the study design, sample size (e.g., more subjects may statistically demonstrate subtler effects), treatment duration, type of MS, medication history, etc.
Let's hope our patent becomes more of the defacto standard for MS treatment.
This is more of a longer term potential catalyst for the company.
I could not find any direct link of the money from the NFL going towards Spaulding Rehabilition Hospital (where the RGN clinical trial was to be performed).
But I did see that Dr. Ross Zafonte who was going to oversee the clinical trial, in the past, has been funded by NIH (who is receiving a the bulk of the money from NFL) and Dept. of Defense (which also is receiving some NFL money). The DOD money portion of the NFL $ seems to be going to 30 Universities and appears to be more for monitoring and collecting data.
Here is a tidbit about Sofpulse a few years ago.
Pulsed electromagnetic fields (PEMF) have been demonstrated to have anti-inflammatory and pro-regenerative effects in animals and humans. We used the FDA-approved Sofpulseâ„¢ (Ivivi Health Sciences, LLC) to study effect of PEMF on infarct size and poststroke inflammation following distal middle cerebral artery occlusion (dMCAO) in mice. Electromagnetic field was applied within 30-45 min after ischemic brain damage and utilized twice a day for 21 consecutive days. Ischemic infarct size was assessed using MRI and histological analysis. At 21 days after dMCAO, the infarct size was significantly (by 26 %) smaller in PEMF-treated animals as compared to controls. Neuroinflammation in these animals was evaluated using specialized cytokine/chemokine PCR array. We demonstrate that PEMF significantly influenced expression profile of pro- and anti-inflammatory factors in the hemisphere ipsilateral to ischemic damage. Importantly, expression of gene encoding major pro-inflammatory cytokine IL-1a was significantly reduced, while expression of major anti-inflammatory IL-10 was significantly increased. PEMF application significantly downregulated genes encoding members of the major pro-apoptotic tumor necrosis factor (TNF) superfamily indicating that the treatment could have both anti-inflammatory and anti-apoptotic effects. Both reduction of infarct size and influence on neuroinflammation could have a potentially important positive impact on the poststroke recovery process, implicating PEMF as a possible adjunctive therapy for stroke patients.
Effect of Pulsed Electromagnetic Field (PEMF) on Infarct Size and Inflammation After Cerebral Ischemia in Mice. Available from: https://www.researchgate.net/publication/260252858_Effect_of_Pulsed_Electromagnetic_Field_PEMF_on_Infarct_Size_and_Inflammation_After_Cerebral_Ischemia_in_Mice
Doing some DD on concussion and PEMF.
What is there not to like about reduction of symptoms AND NO adverse effects?
https://www.drpawluk.com/blog/concussion-and-tbi/
Summary bits from the link above.
Evidence now also tells us that pulsed electromagnetic field therapies can help with, not only the injury itself, but also many of the symptoms resulting from it. In other words, PEMFs are not only useful for symptom management in the person suffering from TBI/concussion, but also have the opportunity to actually heal the brain to reverse the long-term effects of brain damage.
It appears that even very high intensity PEMFs used for extended periods of time produce virtually no adverse effects on the brain and may even decrease the risk of future cancer development and the development of Alzheimer’s/dementia.
Because of the lack of risk seen with the use of TBI, PEMFs should be a routine therapeutic approach in the management of mild to moderate TBI and concussion, and potentially greatly supportive to other adaptive therapies in accelerating recovery and function.
There is much evidence to suggest that there is minimal risk, The safety and risk of PEMFs have been assessed in a number of studies
Frank is the securities lawyer acting as the authorized representative of ENDV for the offering. This is not stating he purchased the $700k portion of the offering.
Section 14 shows there are 13 investors that have been involved as part of the $700k up to that date.
Here is a link about the clinical trial of the Theracap in 2015-2016.
https://clinicaltrials.gov/ct2/show/NCT02643836
Endonovo is focusing on concussion research.
NFL has stepped up their efforts in concussion research.
New PR from NFL
http://www.nfl.com/news/story/0ap3000000903014/article/nfl-announces-grants-toward-advancement-of-neuroscience
With the marketing reach of the NFL, would be HUGE news if our technology becomes the remedy to assist with the healing of concussions.
Thanks for the info. I can sleep better at night knowing ENDV will play it smart with the financing.
They need to attend this conference:
https://www.bio.org/events/bio-ceo-investor-conference
BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Feb 12 - 13
I just sold. Needed the $ for a BIO play next week.
Good luck to you.
I was wondering if ENDV would do anything with the Traumatic Brain Injury Conference May 16-17.
Might be too early.
Even if ENDV does not have results, they should be attending these conferences and networking. Get the ENDV name out there.
The good thing at this low SP, we are averaging 3m shares dilution each week.
Based on 187m remaining to reach 500m A/S, we have 62 weeks to max out if we remained at this share price.
No way we remain at this low level for much longer. I think we are safe from maxing out any time soon.
My concern is if the company does a R/S as a shortcut to get uplisted faster. I don't know if we'll be able to reach and sustain the required SP to be uplisted on our own merit. We can't seem to gain on good news lately.
O/S shares as of this AM
312,756,585
Hola.
Taking a ride with you here also.
I have a small position from 9.65.
And I want to see the winning result of our bet <grin>
Do you think this acquisition might be causing delay with the further advancement of the heart study?
Why would ENDV post in a PR they will submit results @ a scientific meeting in 2018 and not say what the next stage of testing will be or any mention of working under FDA clinical testing guidelines for FDA approval as the next catalyst? They want to get peer opinions and suggestions before the next stage of testing?
I wonder if the CNS disorder study is becoming the primary focus since it is further along? Do you know exactly what stage of study the CNS disorder is at? I believe you mentioned it is in final clinical stage (at least past pre-clinical)?
Any estimate of timeframe for this study to be completed for final review?